Andrew Bolton at CK Science is currently recruiting for a Principal Sustainability Consultant to join a world leading Consultancy on a full time, permanent basis. There is flexibility on location of this role, to be based at their site in Surrey, London, Buckinghamshire or Greater Manchester.
As a Principal Sustainability Consultant, you will be joining the UK Sustainability Team providing consultancy services to customers within the Chemical, Food & Beverage, Automotive, Packaging and other industries across the EMEA. Your responsibilities will include:
Project management of sustainability studies.
Running Life Cycle Assessments (LCAs) using SimaPro LCA software and carbon footprints analysis.
Writing up of project reports and documentation.
Providing support to customer teams throughout the projects.
As a Principal Sustainability Consultant, you will have the following qualifications, skills & experience:
Demonstrated experience carrying out Life Cycle Assessments using SimaPro LCA software.
Experience applying sustainability data to industry / business applications.
Due to the flexibility within the team, there is room for negotiation on making the role more junior or more senior depending on skills & experience offered.
As a Principal Sustainability Consultant you will be joining an industry leading name in Sustainability Consultancy who in return offers a negotiable salary depending on experience and excellent benefits.
For more information or to apply to the role of Principal Sustainability Consultant, please contact Andrew Bolton at CK Science on 01438 723500 or email firstname.lastname@example.org. Please quote reference ST24850 in all correspondence.
Richard Jones, pro vice-chancellor of research and development at Sheffield University, believes this “is good news for us in an environment in which our own research councils’ funding is being squeezed.” Despite the funding having no real guarantees the ERC funding has traditionally led to good results; such as the winner of the Nobel Prize for Physics in 2010, Konstantin Novoselov of the University of Manchester, being able to conduct his research thanks to an ERC grant. Around €80 billion in GDP growth and 450,000 jobs are expected to be created in the next 15 years thanks to the increased funds.
As reported on the BBC News website, SSL International, makers of Durex condoms and Scholl footcare, is to be sold to Reckitt Benckiser, the company behind such brands as Cillit Bang and Finish dishwasher tablets. The deal values SSL at £2.54bn.
The purchase of SSL will widen Reckitt’s health care division and is expected to boost business in China and Japan.
SSL employs approximately 10,000 people worldwide. It has headquarters in London along with manufacturing sites in Manchester, County Durham and Cornwall. SSL is a global company with operations in over 30 countries including China. India and Thailand as well as the UK.
The Slough-based Reckitt Benckiser employs approximately 25,000 people globally.
Both Reckitt and SSL have already warned that the takeover could lead to job cuts.
The Manchester-based chemicals company, Akcros Chemicals has received more than £7m of funding.
The chemicals company, which provides additives used in the manufacture of plastic products, was forced to refinance as a result of the collapse of the Icelandic bank, Landsbanki.
Akcros was then approached by a number of banks before agreeing a flexible working capital facility with RBS’s asset-based lending (ABL) division, RBS Invoice Finance. The bank’s asset finance arm, Lombard, also provided new lending of approximately £700,000 to fund investment in new machinery at Akcros’s Eccles base.
Speaking of the funding injection, Richard Catchpole, Chief Executive Officer of Akcros Chemicals said “We are delighted to have agreed a new ABL facility with RBS, which provides us with the security and flexibility we require to achieve our growth objectives.
“Having to refinance during the depths of a recession was not ideal, but the strong relationship that we built with the team over the course of several months and the RBS ability to deliver a full one-stop-shop solution was key to us choosing them.
“During the downturn, we took action to align our business to the changing landscape and have managed to keep growing over the past year or so by developing new product lines and winning new customers in overseas markets.
“The results we’ve produced over the last year or so have justified our confidence in this strategy and the funding from RBS gives us security and flexibility as we continue to grow.”
Akcros Chemicals has an annual turnover of £60m and its products are exported to more than 50 countries worldwide. The chemical company employs 140 staff at its Manchester site, with the remainder working at its US subsidiary in New Jersey.
A Process Chemist is needed to work on scale up projects for a company which specialises in the development, manufacture and supply of metals and inorganics based in Manchester, North West, UK.
Working as a Process Chemist, your mail roles and responsibilities will include focusing on the development of new processes and furthering products along the new product development system. Projects may include topics such as identifying new or modified equipment and setting up and overseeing trials. These could be located either onsite or at suppliers’ locations.
As a Process Chemist, you will also be involved in the evaluation of technology and installation and commissioning of the equipment recommended. Projects could also include the development of new continuous processes for current batch processes, or identifying improvements and/or cost savings to existing processes. New products involving raw materials which are not currently used may require special equipment for safe handling and all stages of operation.
This Process Chemist role will involve working closely with technical and other staff as well as external contacts, and there may be a requirement to write risk assessments and SOPs for new equipment.
The ideal candidate for this Process Chemist job will be educated to a minimum degree level or equivalent in a Chemistry related discipline and will hold a postgraduate qualification inn Chemical Engineering.
The following skills, experience and competencies are also required for this Process Chemist job:
2-3 years minimum experience post qualification;
A background in one or more of the following inorganic chemistry, catalysis, ceramics, sorption;
Direct experience in process scale up is essential;
Good communication skills;
Good decision making and problem solving skills are essential to the role. Experience of particle size analysis, flow and surface area experiments would be beneficial as well as of kilns and milling.
Experience in Chemical/Process Engineering would be a distinct advantage.
This Process Chemist job is primarily a day role but candidates must be willing to work shifts if required – these will be 6am-2pm and 2pm – 10pm. An occasional night shift may also be required should the project require it though this would be very rare.
How to Apply
For more information, or to apply for this Process Chemist job, please contact Victoria Walker on 0114 283 9956 or email email@example.com. Please quote reference SH19617 in all correspondence.
In partnership with the NIHR Manchester Biomedical Research Centre, scientists at the University of Manchester and GlaxoSmithKline (GSK) will be working together to investigate how the biological clock controls inflammation in lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD).
It is hoped that the £500,000 study, which will be funded by GSK, will lead to the development of new drugs that will target how the internal body clock regulates the severity of inflammation. The team at the University of Manchester will be headed up by Professors Andrew Loudon, David Ray and Kath Else. This team will work closely with colleagues in the Discovery Biology group at GSK.
Speaking of the collaboration, Professor Loudon or the faculty of life sciences, stated:
“Many inflammatory diseases are highly rhythmic in presentation and often worse at night. We believe there is also a strong rhythmic control. It has long been speculated that asthma and other inflammatory conditions have an underlying clock mechanism controlling the severity of the disease. These clocks are all over the body, including in cells responsible for the immune response in the lung. In addition the way we metabolise drugs is highly rhythmic. Our aim is to gain a sufficient understanding of this process so we can target key parts with specific new drugs.
“We are working with GSK not only to develop new drugs to alleviate symptoms but also reveal optimal timing of therapy, known as chronotherapy. This is a new and exciting area of research. It is being taken very seriously in France, for example, where researchers have for some time been studying the importance of timing of chemotherapy in cancer. This study is just one at the beginning of an exciting new phase in circadian rhythm research.”
Inflammatory diseases of the lung are a major cause of mortality world-wide. In the case of COPD, the progression of this inflammatory disease is irreversible once commenced. In the UK 27,478 people died as a result of COPD in 2004. Other diseases with an inflammatory aspect include asthma, which is a predisposition to chronic inflammation of the lungs in which the airways are reversibly narrowed.